Indications for: Ticlopidine HCl
To reduce the risk of thrombotic stroke in selected patients intolerant of aspirin.
250mg twice daily with food.
Ticlopidine HCl Contraindications:
Hematopoietic disorders including neutropenia, thrombocytopenia, or history of thrombotic thrombocytopenic purpura (TTP). Hemostatic or active bleeding disorders. Severe hepatic impairment.
Ticlopidine HCl Warnings/Precautions:
Monitor for hematologic toxicity at baseline, every 2 weeks for the first 3 months, and for 2 weeks after discontinuation; test more frequently if signs of hematological changes occur. Discontinue if neutropenia or TTP occur. Renal or hepatic impairment. Bleeding risk (eg, ulcers). Discontinue 10–14 days before surgery. Hyperlipidemia. Pregnancy (Cat.B). Nursing mothers: not recommended.
Ticlopidine HCl Classification:
Platelet aggregation inhibitor.
Ticlopidine HCl Interactions:
Discontinue anticoagulants, fibrinolytics before use. Avoid aspirin. Potentiates aspirin, NSAIDs, anticoagulants, antipyrine, theophylline. Antacids reduce absorption. May be potentiated by cimetidine. Monitor phenytoin. May antagonize digoxin. Caution with propranolol, drugs that increase risk of bleeding, and drugs metabolized by CYP450.
Diarrhea, GI upset, rash, neutropenia, pruritus, dizziness, anorexia, abnormal liver function tests, bleeding complications, hyperlipidemia, TTP, aplastic anemia, agranulocytosis, other blood dyscrasis, jaundice.
Formerly known under the brand name Ticlid.